Ardelyx shares rise 11.46% intraday after multi-year LPGA partnership to break digestive health stigma.

Ardelyx surged 11.46% intraday following the announcement of a multi-year partnership with the LPGA to raise awareness of irritable bowel syndrome with constipation (IBS-C). The collaboration aims to break the stigma around digestive health by leveraging the LPGA’s platform to educate and mobilize patients, aligning with Ardelyx’s commercial goals for IBSRELA. The partnership, highlighted in multiple news reports, underscores the company’s strategy to expand market reach for its IBS-C treatment, directly linking to the stock’s sharp intraday gain.